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1. INTRODUCTION {#apt15185-sec-0006}
===============

Gastro‐oesophageal reflux disease (GERD) is a prevalent digestive disease that results from reflux of gastric contents into the oesophagus.[1](#apt15185-bib-0001){ref-type="ref"}, [2](#apt15185-bib-0002){ref-type="ref"} The prevalence of GERD in East Asian countries is increasing, and is reported to be 4.5%‐15.7%[3](#apt15185-bib-0003){ref-type="ref"}, [4](#apt15185-bib-0004){ref-type="ref"} Population‐based studies have shown that the prevalence of symptom‐based GERD in East Asia was 5.2%‐8.5% from 2005 to 2010. According to the Korean National Health Insurance claim, data also show that the prevalence of GERD in Korea is increasing rapidly from 4.6% to 7.3% between 2005 and 2008.[5](#apt15185-bib-0005){ref-type="ref"}, [6](#apt15185-bib-0006){ref-type="ref"}

The spectrum of GERD includes erosive oesophagitis (EE) and non‐erosive reflux disease (NERD). EE is characterised by the presence of oesophageal mucosal erosions induced by the reflux of gastric contents from the stomach, which can be diagnosed by endoscopy. Currently, proton‐pump inhibitors (PPIs) are the first‐line drug for treating EE and controlling symptoms.[7](#apt15185-bib-0007){ref-type="ref"} Studies in patients with EE have shown high healing rates (88%‐96%) after 8‐week treatment with a PPI once daily.[8](#apt15185-bib-0008){ref-type="ref"}, [9](#apt15185-bib-0009){ref-type="ref"}, [10](#apt15185-bib-0010){ref-type="ref"} However, some patients may have endoscopic evidence of oesophagitis and/or reflux symptoms despite PPI therapy.[11](#apt15185-bib-0011){ref-type="ref"}, [12](#apt15185-bib-0012){ref-type="ref"}, [13](#apt15185-bib-0013){ref-type="ref"}

Tegoprazan, (S)‐4‐((5,7‐difluorochroman‐4‐yl)oxy)‐*N,N*,2‐trimethyl‐1*H*‐benzo\[d\]imidazole‐6‐carboxamide, was developed in South Korea by CJ Healthcare Corp. It is a novel, potent, and highly selective potassium‐competitive acid blocker (P‐CAB) with a mechanism of action distinct from that of the PPIs.[14](#apt15185-bib-0014){ref-type="ref"}

Unlike PPIs, that require a chemical transformation into their active form and bind covalently to the gastric H^+^ */*K^+^‐ATPase, tegoprazan inhibits H^+^ */*K^+^‐ATPase in a reversible and K^+^‐competitive manner without a need for any conversion. It is an acid‐resistant weak base which can remain in a highly acidic canaliculi of gastric parietal cells.

Nonclinical studies have shown that this compound suppresses gastric acid secretion faster and more potently than esomeprazole treated group.[14](#apt15185-bib-0014){ref-type="ref"} The therapeutic potential of tegoprazan may be derived from its ability to accumulate at high concentrations in the canaliculi of gastric parietal cells. Consequently, it is slowly cleared from the gastric glands and exerts its effects independent of acid levels, leading to a strong and sustained effect.[14](#apt15185-bib-0014){ref-type="ref"} Tegoprazan has been demonstrated a strong antisecretory potency and a fast onset of action in several phase I studies.[15](#apt15185-bib-0015){ref-type="ref"} Its suppressive effect on acid secretion reaches a maximum plateau within 0.5‐1 hour after administration at a dose of 50, 100 or 200 mg.[15](#apt15185-bib-0015){ref-type="ref"} The food effect on pharmacodynamics and pharmacokinetics study indicated that the efficacy of tegoprazan is independent of food intake.[16](#apt15185-bib-0016){ref-type="ref"} The pharmacodyniamc data of tegoprazan indicate that the 50 and 100 mg doses increase intragastric pH to ≥4 significantly more than the dexlansoprazole 60 mg with evening dosing.[17](#apt15185-bib-0017){ref-type="ref"} In a phase II dose‐ranging study, the proportions of patients with EE who were healed up to week 8 were comparable between tegoprazan (50‐200 mg, once daily) and esomeprazole (40 mg, once daily).[18](#apt15185-bib-0018){ref-type="ref"}

On the basis of these phase I pharmacodynamics data and phase II dose finding study in EE patients, it was hypothesised that treatment with tegoprazan could produce at least comparable clinical efficacy in healing of oesophagitis and symptom control compared with the treatment of PPIs.

Esomeprazole has been shown to have better acid control than lansoprazole, omeprazole and rabeprazole,[19](#apt15185-bib-0019){ref-type="ref"}, [20](#apt15185-bib-0020){ref-type="ref"} and higher oesophagitis healing rates than lansoprazole and omeprazole.[21](#apt15185-bib-0021){ref-type="ref"} Therefore, esomeprazole 40 mg was considered to be the most appropriate comparator to tegoprazan.

The purpose of this phase III study was to verify the non‐inferiority of safety and efficacy of tegoprazan 50 and 100 mg to those of esomeprazole 40 mg in patients with EE.

2. MATERIALS AND METHODS {#apt15185-sec-0007}
========================

2.1. Study design and treatments {#apt15185-sec-0008}
--------------------------------

Adult patients with endoscopically confirmed EE at screening were eligible for enrolment into the 8‐week, double‐blind, three‐armed, active‐controlled comparison study (ClinicalTrials.gov identifier NCT03006874). The study was designed to verify the non‐inferiority of tegoprazan 50 and 100 mg to esomeprazole 40 mg in patients with EE. The study was conducted at 27 sites in South Korea from October 2016 to August 2017.

The study protocol was approved by the Institutional Review Board at each study site. The study was conducted in accordance with the Declaration of Helsinki and the International Harmonisation on Conference Harmonised Tripartite Guideline for Good Clinical Practice. All participants provided written informed consent before they were enrolled. The participants were required to discontinue PPI use during the screening period and throughout the study period. The screening period was up to 14 days. Endoscopy was performed to evaluate the presence and severity of EE based on the Los Angeles (LA) Classification system during the screening period, and then at the week 4, and week 8 or final visit (if not healed by week 4).

Following the screening period, patients were randomised 1:1:1 to receive either tegoprazan (50 or 100 mg) or esomeprazole (40 mg). The doses were administered once daily for 4 or 8 weeks via the oral route. Treatment was completed after 4 or 8 weeks if healing of mucosal lesions was endoscopically confirmed.

2.2. Study subjects {#apt15185-sec-0009}
-------------------

Male or female patients aged ≥20 years with endoscopically confirmed EE (LA Classification Grades A‐D) were eligible for inclusion in the study. The major exclusion criteria included complications associated with oesophagitis, active gastric or duodenal ulcer, gastrointestinal bleeding, Zollinger‐Ellison syndrome, malignancy, AIDS, hepatitis, eosinophilic oesophagitis, a history of acid‐lowering surgery, previous oesophageal or gastric surgery, malignancy within 5 years prior to enrolment, primary oesophageal motility disorders, irritable bowel syndrome, inflammatory bowel disease or any of the following abnormal laboratory test values at the screening (blood urea nitrogen and serum creatinine level, \>1.5 upper limit of normal \[ULN\]; total bilirubin level and serum levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and gamma glutamyltransferase, \>2ULN). Pregnant and lactating subjects and those who needed treatment with nonsteroidal anti‐inflammatory drugs or surgery requiring hospitalisation were excluded from the study. Any female of child‐bearing potential who was sexually active was required to use adequate contraceptive measures during the study period. Patients were not allowed to concomitantly use any medications that could affect efficacy evaluation. These included proton pump inhibitors (within 2 weeks prior to enrolment), histamine receptor 2 blocking agents, antidepressants, antipsychotics and antianxiety drugs.

2.3. Study protocol {#apt15185-sec-0010}
-------------------

The patients were randomised to receive either tegoprazan or esomeprazole. All randomisation information was securely stored and could be accessed by authorised personnel only. A double‐dummy method, using matching tegoprazan and esomeprazole placebo tablets, was employed to ensure that the study was double‐blinded. All medications were provided in sealed boxes and supplied by the medication supervisor to ensure blinded allocation.

At the start of the screening period, patient demographics and other baseline characteristics were recorded, including medical history, concurrent medical conditions, medication history and concomitant medications. At the start of the screening period, clinical laboratory tests (complete blood count, serum chemistry and urinalysis), physical examination, pregnancy test, electrocardiogram test and Helicobacter pylori test were performed. In addition, vital signs were assessed. At week 4 and 8 (or upon early termination), physical examination, clinical laboratory tests and pregnancy test were performed. Additionally, vital signs (including electrocardiogram \[ECG\]), adverse events, concomitant medication, patients' diary and treatment compliance were checked.

Endoscopy was performed by principal investigators with at least 3 years of endoscopy experience at the start of the screening period and at weeks 4 and 8 (or upon early termination). Severities of EE were defined based on the endoscopic findings according to the LA Classification from grade A to D. Healed EE was defined as the absence of oesophageal mucosal erosions or ulcers on oesophagogastroduodenoscopy. Changes in symptoms were assessed using the Reflux Disease Questionnaire (RDQ), which is a 12‐item self‐administered questionnaire designed to assess the frequency and severity of heartburn, acid regurgitation and dyspepsia. Mean RDQ score change was checked from baseline to week 4 or 8. Other patient‐reported outcome measures included GERD Health‐Related Quality of Life (GERD*‐*HRQL) scores, GERD symptoms and compliance with treatment. The GERD‐HRQL scale has 11 items that focus on heartburn symptoms, dysphagia, medication effects and the patient\'s health condition. Each item is scored from 0 to 5, with a higher score indicating a worse quality of life. Patients rated the severity of heartburn and regurgitation at daytime and night‐time according to the four‐point scale (0: none; 1: mild; 2: moderate; 3: severe) using daily diaries.

2.4. Outcome evaluation {#apt15185-sec-0011}
-----------------------

The primary endpoint was the proportion of EE patients with healed EE confirmed by endoscopy up to week 8. The secondary endpoints included subjective symptoms, such as changes in RDQ scores, the percentage of days without major symptoms as reported in the patient\'s diary, GERD‐HRQL score, and the proportion of EE patients with healed EE confirmed by endoscopy at week 4.

Safety was assessed by physical examinations and the analysis of adverse events, laboratory test values, ECG findings and vital signs. The frequency and severity of adverse events and concomitant medications were monitored throughout the study. Treatment‐emergent adverse event (TEAE) was defined as an adverse event occurred during treatment, representing a change from baseline. All TEAEs were graded based on severity as severe, moderate or mild by the investigator. A drug*‐*related TEAE was an adverse event that was deemed by the investigator as possibly related or as related to the study drug. A serious TEAE was defined as an adverse event that could cause death, hospitalisation, disability, congenital anomaly or a life‐threatening adverse event.

2.5. Statistical analysis {#apt15185-sec-0012}
-------------------------

Based on the results of a phase II study in which the proportion of EE patients showing healed EE up to week 8 was 96.0% for tegoprazan 50 mg, 97.9% for tegoprazan 100 mg, and 96.1% for esomeprazole 40 mg, the sample size in the present study was calculated 100 subjects per treatment group. A power of ≥90% was used to detect non‐inferiority of tegoprazan to esomeprazole with a non‐inferiority margin of 10%.

For the primary endpoint, the proportion of patients with healed EE up to week 8 was calculated in the per protocol set (PPS) population. The non‐inferiority of tegoprazan to esomeprazole was tested by comparing the lower bound of two‐sided 95% confidence intervals with a non‐inferiority margin of 10%. The same analyses were performed for the proportion of patients with healed EE up to week 4. Wilcoxon\'s rank sum test was performed to compare the change of symptom scores between groups.

Besides the PPS analysis (n = 271), the intention‐to‐treat (ITT) analysis (n = 300) was also performed for efficacy analysis.

3. RESULTS {#apt15185-sec-0013}
==========

3.1. Study subjects {#apt15185-sec-0014}
-------------------

Out of the 452 patients enrolled in the study, 302 eligible patients were randomised to receive either tegoprazan (50 mg, n = 100; 100 mg, n = 102) or esomeprazole (n = 100). A total of 286 subjects completed the study (Figure [1](#apt15185-fig-0001){ref-type="fig"}).

![Randomisation protocol and patient disposition](APT-49-864-g001){#apt15185-fig-0001}

The treatment groups were comparable regarding the baseline characteristics except the history of smoking. EE severity at baseline was similar between treatment groups (Table [1](#apt15185-tbl-0001){ref-type="table"}).

###### 

Demographic characteristics of the intention‐to‐treat population

  Demographics                                             Tegoprazan            Esomeprazole          
  -------------------------------------------------------- --------------------- --------------------- ---------------------
  Age (y), mean (range)                                    52.7 (21.0‐74.0)      52.8 (20.0‐74.0)      50.4 (21.0‐75.0)
  Males, n (%)                                             62 (62.6)             66 (64.7)             53 (53.5)
  Height (cm), mean (range)                                165.2 (142.5‐187.0)   166.1 (150.2‐183.0)   165.0 (145.3‐189.0)
  Weight (kg), mean (range)                                66.8 (43.0‐110.8)     66.4 (42.5‐112.5)     65.5 (40.7‐99.5)
  Alcohol consumption, n (%)                               42 (42.4)             45 (44.1)             39 (39.4)
  Smoking, n (%)                                           27 (27.3)             17 (16.7)             13 (13.1)
  *Helicobacter pylori* infection status positive, n (%)   23 (23.2)             21 (20.6)             21 (21.2)
  Baseline LA Classification grade A, n (%)                66 (66.7)             67 (65.7)             66 (66.7)
  Baseline LA Classification grade B, n (%)                29 (29.3)             30 (29.4)             29 (29.3)
  Baseline LA Classification grades C/D, n (%)             4 (4.0)               5 (4.9)               4 (4.0)

LA, Los Angeles.

John Wiley & Sons, Ltd

The overall compliance rate exceeded 95% in all the treatment groups. The mean compliance rates were 98.1%, 97.9% and 97.1% in the tegoprazan 50 mg, tegoprazan 100 mg and esomeprazole 40 mg, respectively.

Sixteen patients (5.3%) did not complete the study: five in the tegoprazan 50 mg group, four in the tegoprazan 100 mg group and seven in the esomeprazole group. The details of each treatment group are summarised in the flow chart in Figure [1](#apt15185-fig-0001){ref-type="fig"}.

3.2. Healing rate of EE {#apt15185-sec-0015}
-----------------------

In the PPS population, the proportion of patients with healed EE over the 8‐week treatment period was 98.9%, 98.9% and 98.9% in the tegoprazan 50 and 100 mg and esomeprazole 40 mg groups, respectively. The lower bound of the two‐sided 95% confidence interval of the treatment difference (tegoprazan‐esomeprazole) met the prespecified non‐inferiority criteria (Table [2](#apt15185-tbl-0002){ref-type="table"}). Both doses of tegoprazan were non‐inferior to esomeprazole 40 mg (*P *\<* *0.0001). In the ITT analysis, the healing rates up to week 8 were comparable between the tegoprazan (50 and 100 mg) and esomeprazole (40 mg) groups. There were no statistically significant differences between the treatment groups (Table [2](#apt15185-tbl-0002){ref-type="table"}).

###### 

Healing rates (%) of erosive oesophagitis up to week 8

  Treatment            \% Patients healed   Difference from esomeprazole   \[95% CIs\]      *P*‐value[a](#apt15185-note-0005){ref-type="fn"} non‐inferiority
  -------------------- -------------------- ------------------------------ ---------------- ------------------------------------------------------------------
  Week 8 PPS                                                                                
  Tegoprazan 50 mg     98.9                 0.1                            \[−3.0, 3.1\]    \<.0001
  Tegoprazan 100 mg    98.9                 0.0                            \[−3.0, 3.1\]    \<.0001
  Esomeprazole 40 mg   98.9                                                                 
  ITT                                                                                       
  Tegoprazan 50 mg     96.0                 3.0                            \[−3.3, 9.4\]    \<.0001
  Tegoprazan 100 mg    95.1                 2.2                            \[−4.4, 8.7\]    0.0001
  Esomeprazole 40 mg   92.9                                                                 
  Week 4 PPS                                                                                
  Tegoprazan 50 mg     91.3                 −3.0                           \[−10.5, 4.5\]   0.0343
  Tegoprazan 100 mg    93.4                 −0.9                           \[−7.9, 6.1\]    0.0056
  Esomeprazole 40 mg   94.3                                                                 
  ITT                                                                                       
  Tegoprazan 50 mg     87.9                 0.0                            \[−9.1, 9.1\]    0.0156
  Tegoprazan 100 mg    90.2                 2.3                            \[−6.3, 11.0\]   0.0026
  Esomeprazole 40 mg   87.9                                                                 

CIs, confidence intervals; ITT, intention‐to‐treat; PPS, per protocol set.

Non‐inferiority test at the significant level 0.05 (two‐sided).

John Wiley & Sons, Ltd

In the PPS population, the proportion of patients with healed EE over the 4‐week treatment period was 91.3% and 93.4% in the tegoprazan 50 and 100 mg groups, respectively, which were similar to that of the esomeprazole group (94.3%). The healing rate at week 4 in the ITT analysis was 87.9% in the tegoprazan 50 mg group (n = 99), 90.2% in the tegoprazan 100 mg group (n = 102) and 87.9% in the esomeprazole 40 mg group (n = 99). In the ITT analysis, tegoprazan 50 and 100 mg were non‐inferior to esomeprazole 40 mg (*P = *0.0156 and 0.0026, respectively).

3.3. Symptom response {#apt15185-sec-0016}
---------------------

Patients in all the three treatment groups reported significant improvement in the severity and frequency of heartburn, dyspepsia and regurgitation, which were assessed at weeks 4 and 8 using RDQ scores (*P *\<* *0.0001). Mean RDQ severity and frequency scores significantly decreased after the 4‐ and 8‐week treatments with the investigational drugs. There were no significant differences between the treatment groups regarding mean changes in RDQ total scores at either week 4 or 8. Mean reductions in the severity/frequency of heartburn and dyspepsia did not show statistically significant differences between the treatment groups at week 8.

Reductions in the regurgitation severity and frequency were statistically higher in the tegoprazan 50 mg group at week 4 and 8 than in the esomeprazole 40 mg group. However, significant difference (*P‐*value) of regurgitation at baseline was observed between the treatment groups, and the least‐squares mean change in the regurgitation score from baseline to week 4 or 8 was analysed additionally. There was no statistically significant difference between the three treatment groups after adjustment of baseline (Table [3](#apt15185-tbl-0003){ref-type="table"}).

###### 

Mean RDQ symptom scores at baseline, week 4 and 8 (per protocol set)

  Mean RDQ        Tegoprazan   Esomeprazole                                                             
  --------------- ------------ -------------- -------- ---------- -------- -------- ---------- -------- --------
  Severity        Baseline     Week 4         Week 8   Baseline   Week 4   Week 8   Baseline   Week 4   Week 8
  Major symptom   2.00         0.58           0.58     1.87       0.58     0.58     1.72       0.50     0.48
  Heartburn       1.76         0.53           0.56     1.86       0.62     0.62     1.84       0.48     0.47
  Dyspepsia       1.43         0.41           0.40     1.47       0.38     0.37     1.47       0.45     0.45
  Regurgitation   2.24         0.62           0.60     1.88       0.54     0.54     1.61       0.52     0.50
  Frequency                                                                                             
  Major symptom   2.02         0.88           0.87     2.01       0.85     0.84     1.82       0.78     0.75
  Heartburn       1.75         0.79           0.79     1.97       0.92     0.90     1.89       0.76     0.74
  Dyspepsia       1.54         0.52           0.51     1.49       0.52     0.49     1.57       0.61     0.62
  Regurgitation   2.29         0.97           0.95     2.05       0.77     0.77     1.75       0.79     0.76

RDQ, Reflux Disease Questionnaire.

John Wiley & Sons, Ltd

There was a significant increase in the percentage of days without major symptoms (heartburn and regurgitation) in all the treatment groups, but there were no statistically significant differences between the treatment groups (data not shown). GERD‐HRQL total scores over the 4‐ and 8‐week treatment periods reduced significantly in all the treatment groups. The mean reduction in GERD‐HRQL scores of the tegoprazan‐treated groups was not significantly different from that in the esomeprazole‐treated group (Table [4](#apt15185-tbl-0004){ref-type="table"}).

###### 

GERD‐HRQL score changes from baseline at week 4 and week 8 (per protocol set)

  GERD‐HRQL                                          Tegoprazan   Esomeprazole                                    
  -------------------------------------------------- ------------ -------------- ---------- ---------- ---------- ----------
                                                     Week 4       Week 8         Week 4     Week 8     Week 4     Week 8
  Change from baseline                               −7.9         −8.1           −7.3       −7.3       −6.9       −7.1
  *P*‐value[a](#apt15185-note-0008){ref-type="fn"}   \<0.0001     \<0.0001       \<0.0001   \<0.0001   \<0.0001   \<0.0001
  Difference from esomeprazole                       −1.0         −1.0           −0.4       −0.2       ---        ---
  *P*‐value[b](#apt15185-note-0009){ref-type="fn"}   0.1858       0.1920         0.7560     0.8216     ---        ---

GERD‐HRQL, Gastro‐oesophageal Reflux Disease Health‐Related Quality of Life.

Wilcoxon\'s signed rank test.

Wilcoxon\'s rank sum test.

John Wiley & Sons, Ltd

3.4. Tolerability and safety {#apt15185-sec-0017}
----------------------------

Three hundred patients received at least one dose of a study medication and were included in the safety analyses. Most TEAEs (136/149, 91.3%) were mild in intensity. Two severe TEAEs that were joint injury and breast cancer in the tegoprazan 50 mg group that were "definitely not related" to the investigational drug. There were no severe TEAEs in the tegoprazan and esomeprazole groups. The percentages of patients with more than one TEAE were 28.3%, 23.5% and 30.3% in the tegoprazan 50 mg, tegoprazan 100 mg and esomeprazole 40 mg groups, respectively (Table [5](#apt15185-tbl-0005){ref-type="table"}). Drug‐related TEAEs (≥2%) are shown in Table [6](#apt15185-tbl-0006){ref-type="table"}. Dyspepsia (2.0%) and chest discomfort (2.0%) in the tegoprazan groups, and headache (4.0%) in the esomeprazole group were the most frequently reported drug‐related TEAEs (Table [6](#apt15185-tbl-0006){ref-type="table"}). All the TEAEs disappeared spontaneously without any treatment. The percentage of patients with TEAEs leading to premature discontinuation of treatment was 2.9% in the tegoprazan 50 mg group, 2.9% in the esomeprazole 40 mg group and 3.0% in the tegoprazan 100 mg group. Headache (2% in the esomeprazole 40 mg group) was the most common adverse event that led to discontinuation. The rate of serious TEAEs was 2.0% in the tegoprazan 50 mg group, 2.0% in the tegoprazan 100 mg group and 1.0% in the esomeprazole 40 mg group. All serious TEAEs were considered to be unrelated to the study medication by the investigators. No significant changes in vital signs or ECG findings were observed during the study period.

###### 

Summary of treatment‐emergent adverse events (TEAEs)

                                                                                                                    Tegoprazan   Esomeprazole                                                                                       
  ----------------------------------------------------------------------------------------------------------------- ------------ -------------- ----------- ----------- ----------- ----------------------------------------------- --
  Any TEAE                                                                                                          28 (28.3)    \[43\]         24 (23.5)   \[55\]      30 (30.3)   \[51\]                                          
  Drug‐related TEAE                                                                                                 10 (10.1)    \[17\]         5 (4.9)     \[14\]      11 (11.1)   \[14\]                                          
  Serious TEAE                                                                                                      2 (2.0)      \[2\]          2 (2.0)     \[2\]       1 (1.0)     \[1\]                                           
  Death                                                                                                             0 (0.0)      \[0\]          0 (0.0)     \[0\]       0 (0.0)     \[0\]                                           
  Most frequently reported TEAEs by system organ class and preferred term [a](#apt15185-note-0081){ref-type="fn"}                *P*‐value                                                                                          
  Gastrointestinal disorders                                                                                        10 (10.1)    9 (8.8)                    10 (10.1)               0.9390[b](#apt15185-note-0082){ref-type="fn"}   
  --Diarrhoea                                                                                                       3 (3.0)      5 (4.9)                    1 (1.0)                 0.3093[b](#apt15185-note-0082){ref-type="fn"}   
  Nervous system disorders                                                                                          0 (0.0)      2 (2.0)                    7 (7.1)                 0.0087[c](#apt15185-note-0083){ref-type="fn"}   
  --Headache                                                                                                        0 (0.0)      2 (2.0)                    6 (6.1)                 0.0220[c](#apt15185-note-0083){ref-type="fn"}   
  Infections and infestations                                                                                       6 (6.0)      8 (7.8)                    9 (9.1)                 0.7229[b](#apt15185-note-0082){ref-type="fn"}   
  --Viral upper respiratory tract infection                                                                         4 (4.0)      6 (5.9)                    6 (6.1)                 0.7818[b](#apt15185-note-0082){ref-type="fn"}   

\[F\] = Frequency of TEAEs

N‐dash represents preferred term.

≥3%

Chi‐square test

Fisher\'s exact test.

John Wiley & Sons, Ltd

###### 

Drug‐related treatment‐emergent adverse events (TEAEs) reported by at least 2% of patients in any treatment group

  System organ class/Preferred term   Tegoprazan   Esomeprazole   *P‐*value[a](#apt15185-note-0014){ref-type="fn"}   
  ----------------------------------- ------------ -------------- -------------------------------------------------- --------
  Dyspepsia                           2 (2.0)      1 (1.0)        0 (0.0)                                            0.5467
  Chest discomfort                    2 (2.0)      0 (0.0)        1 (1.0)                                            0.3245
  Headache                            0 (0.0)      1 (1.0)        4 (4.0)                                            0.0196

Fisher\'s exact test.

John Wiley & Sons, Ltd

4. DISCUSSION {#apt15185-sec-0018}
=============

The findings of the current randomised controlled study in 302 patients with EE demonstrated that tegoprazan, when administered at 50 or 100 mg once daily, was non‐inferior to esomeprazole 40 mg regarding the healing rate of EE. Both doses of tegoprazan were highly effective in healing EE. Tegoprazan 100 mg did not provide additional clinical benefit over tegoprazan 50 mg. However, we did not observe any superior results of tegoprazan over esomeprazole since the healing rates in all treatment groups were too high to detect any significant differences.

The healing rates after 4 weeks of treatment were also comparable between the treatment groups, and higher than 90% in all treatment groups. ITT analyses of the healing rate after the 4‐week treatment demonstrated the non‐inferiority of tegoprazan 50 mg to esomeprazole 40 mg.

All these results are consistent with those of a previous phase II dose‐ranging study in EE patients.[18](#apt15185-bib-0018){ref-type="ref"} Subgroup analysis according to the baseline LA grade of oesophagitis revealed no significant differences in healing rates between the two doses of tegoprazan and esomeprazole 40 mg at week 4 and 8 (data not shown).

Treatment with tegoprazan also showed high healing rates (100%) in EE patients with LA grade C/D, although the number of those patients was small (n = 3‐4/group). In South Korea, most of patients with EE have LA grade A or B. Patients with LA grade C or D are relatively rare.[22](#apt15185-bib-0022){ref-type="ref"}, [23](#apt15185-bib-0023){ref-type="ref"}

Currently, two P‐CABs including tegoprazan have been approved for the treatment of GERD. Revaprazan, the first P‐CAB was approved for treating peptic ulcers.[24](#apt15185-bib-0024){ref-type="ref"}, [25](#apt15185-bib-0025){ref-type="ref"} The second P‐CAB clinically available was vonoprazan, which was recently approved for the treatment of EE in Japan.[26](#apt15185-bib-0026){ref-type="ref"}, [27](#apt15185-bib-0027){ref-type="ref"}, [28](#apt15185-bib-0028){ref-type="ref"} Tegoprazan was approved in South Korea in July, 2018 for the treatment of EE and NERD, and it became the first P‐CAB clinically available for treating NERD.[29](#apt15185-bib-0029){ref-type="ref"}, [30](#apt15185-bib-0030){ref-type="ref"}

The present study showed that RDQ scores assessing the severity and frequency of regurgitation significantly decreased more in the tegoprazan 50 mg group than in the esomeprazole group (*P *\<* *0.05, Wilcoxon\'s rank sum test). However, there was significant difference in the baseline score at the baseline between treatment groups. We analysed the regurgitation score change from baseline to 4 or 8 week using Least square mean (data now shown), and found that there was no significant difference of the regurgitation score change among the three treatment groups.

Both tegoprazan and esomeprazole were well tolerated in the current study. Two patients in the tegoprazan 50 mg group, two in the tegoprazan 100 mg group and three in the esomeprazole group discontinued treatment because of TEAEs. Dyspepsia and chest discomfort were drug‐related TEAEs with an incidence of ≥2% in the tegoprazan 50 mg group (Table [6](#apt15185-tbl-0006){ref-type="table"}). Headache was the most frequently reported drug‐related TEAE in the esomeprazole 40 mg group, that was the only drug‐related TEAE showing a significant difference compared to the other group (*P *=* *0.0196). Diarrhoea was the most frequent TEAE in the tegoprazan 50 and 100 mg groups. However, there was no significant difference in the occurrence rate of diarrhoea between the three treatment groups (*P *=* *0.3093).

Furthermore, there were no newly identified safety signals or any significant changes in vital signs, ECG findings or other safety signals. Overall, all the treatments were well tolerated. Moreover, the incidences of TEAEs, drug‐related TEAEs, serious TEAEs and TEAEs leading to drug discontinuation were similar between the tegoprazan‐ and esomeprazole‐treated groups. The majority (91.3%) of TEAEs were considered mild in severity and not related to the study drug.

In conclusion, once daily administration of tegoprazan 50 or 100 mg shows non‐inferior efficacy in healing EE and tolerability to that of esomeprazole 40 mg.
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